Living Medical
Textbook
From Projects In Knowledge 		 
Oncology
Women's Cancers Edition
Table of Contents  |  CME Information  | Technical Requirements  | Login 
  /1863/iPhoneAd/1863iPhoneAd.gif [NO]
Chapter 1
Chemotherapy in Recurrent or Metastatic Cervical Cancer
Last Reviewed: August 23, 2010
Chapter 2
Current Management of Endometrial Cancer
Last Reviewed: August 23, 2010
Chapter 3
Frontline Management of Ovarian Cancer
Last Reviewed: August 23, 2010
Chapter 4
Recurrent Ovarian Cancer: State of the State
Last Reviewed: August 23, 2010
Chapter 5
Early Breast Cancer—Tumor Genetic Profiling in The 21st Century
Last Reviewed: August 23, 2010
Chapter 6
Targeted Agents and Chemotherapy Options for HER2-Positive and HER2-Negative Metastatic Breast Cancer
Last Reviewed: August 23, 2010


Oncology News powered by
MedPage Today
 
ACCME Disclaimer
 
Chapter 4 – Recurrent Ovarian Cancer: State of the State

Contributing Editor
Robert L. Coleman Robert L. Coleman, MD
Professor & Director of Clinical Research
Department of Gynecologic Oncology
University of Texas MD Anderson Cancer Center
Houston, Texas
top

Activity Goal
The goal of this CME activity is to examine current and emerging strategies for treating and managing patients with ovarian cancer.

Target Audience
This CME activity is designed for medical oncology clinicians, gynecologists, primary care physicians and other clinicians who interact with and/or treat women with ovarian cancer.
Learning Objectives
•   Distinguish between platinum-refractory, platinum-resistant, and platinum-sensitive disease in order to select therapeutic regimens most likely to produce response and progression-free survival in women with recurrent ovarian cancer.
•   Evaluate the role of therapeutic regimens—including standard chemotherapy and targeted agents—in improving quality of life and prolonging survival in women with recurrent ovarian cancer.

top
CME Information: Physicians
Statement of Accreditation
Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation
Projects In Knowledge designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
top
Disclosure Information
 The Disclosure Policy of Projects In Knowledge requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials. For complete prescribing information on the products discussed during this CME activity, please see your current Physicians' Desk Reference (PDR).

Robert L. Coleman, MD, has received grant/research support from American Bioscience, Morphotek, Inc, and Novartis Pharmaceuticals Corporation; is a consultant for and on the advisory board for Eli Lilly and Company, Genentech, Inc, GlaxoSmithKline, Ortho Biotech Products, LP, Pfizer Inc, and Precision Therapuetics; and is on the speakers bureau of Eli Lilly and Company, GlaxoSmithKline, and Ortho Biotech Products, LP.

Nancy J. Nordenson, MT (ASCP), MFA (medical writer), has disclosed no significant relationships.

Off-Label Drug Statement: The following drugs are not approved for the treatment of recurrent ovarian cancer: altretamine, bevacizumab, canfosfamide, cediranib, docetaxel, etoposide, ifosfamide, oxaliplatin, tamoxifen, trabectedin, treosulfan, and vinorelbine.

Peer Reviewer has disclosed no significant relationships.

Projects In Knowledge’s staff members have no significant relationships to disclose.

top

Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.

The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.

This CME activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.

Contract for Mutual Responsibility in CME
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.

For more information on the contract, click here

Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.

top 1863.03


Launch Activity
 
Projects In Knowledge®


Peer Reviewed
These independent CME activities are supported by educational grants from

Bristol-Myers Squibb

Genentech Inc.

Novartis Pharmaceutical Corporation

OrthoBiotech Inc.

Pfizer Inc..

Release Date: January 19, 2009.

Termination Date: September 15, 2010.

Estimated time for completion of this activity: 2.0 hours

CME Instructions
To obtain CME credit for this activity:
  1. Read the chapter carefully.
  2. Achieve a passing score on the posttest.
  3. Complete/submit the posttest and evaluation.
  4. Instantly access and print out your certificate.

There is no fee for this activity.































 
 




ABOUT US  |  CONTACT US  |  CONTRACT  |  DIRECTIONS  |  PRIVACY POLICY  |  RESOURCES
Copyright © 1997-2010, Projects In Knowledge, Inc. All rights reserved.
PROJECTS IN KNOWLEDGE • Overlook at Great Notch • 150 Clove Road, 10th Floor • Little Falls, New Jersey 07424 (973) 890-8988